Table 1. Study Characteristics of 85 Included Comparisons.
| Study characteristic | No. (%)a |
|---|---|
| Year of publication | |
| 2000-2005 | 2 (2) |
| 2006-2011 | 7 (8) |
| 2012-2017 | 33 (39) |
| 2018-2022 | 43 (51) |
| Study location | |
| North America | 64 (75) |
| Asia | 9 (11) |
| Europe | 9 (11) |
| Australia | 3 (4) |
| Cancer | |
| Hematologic | 18 (21) |
| Breast | 14 (16) |
| Lung | 12 (14) |
| CNS | 6 (7) |
| Prostate | 6 (7) |
| Melanoma | 5 (6) |
| Pancreatic | 4 (5) |
| Otherb | 20 (24) |
| Advanced/metastatic patients | 28 (33) |
| Patient populationc | |
| Adult | 75 (89) |
| Pediatric | 5 (6) |
| Mixed | 4 (5) |
| Routine care group institution source | |
| Single institution | 21 (25) |
| Multiple institutions | 64 (75) |
| Routine care group data source | |
| Registry | 67 (79) |
| Medical records | 18 (21) |
| Sample size, median (IQR) | |
| Trial participants | 209 (96-397) |
| Routine care patients | 409 (173-1523) |
| Age, median (IQR), yc,d | |
| Trial participants | 59 (53.3-62.0) |
| Routine care patients | 62 (57-67) |
| Male sex, median (IQR), %c,e | |
| Trial participants | 57 (0-70.5) |
| Routine care patients | 54.5 (0-67.5) |
| Female sex, median (IQR), %c,e | |
| Trial participants | 42 (28.5-99.0) |
| Routine care patients | 44.5 (32.5-100.0) |
Abbreviation: CNS, central nervous system.
a
Percentages may not add to 100 due to rounding.
b
Other cancer types included bladder, cervical, colorectal, esophageal, gastric, head and neck, kidney, ovarian, and mixed solid tumors.
c
Excludes studies with missing data.
d
Unweighted medians of reported means or medians.
e
Unweighted medians of reported percentages.